Open AccessTherapeutical aspect of trichomoniasis
Author(s) -
Jelica Vukičević,
Jasmina Jankićević
Publication year - 2003
Publication title -
srpski arhiv za celokupno lekarstvo
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.135
H-Index - 17
eISSN - 2406-0895
pISSN - 0370-8179
DOI - 10.2298/sarh0304156v
Subject(s) - trichomoniasis , medicine , trichomonas vaginalis , metronidazole , trichomonas , genitourinary system , asymptomatic , incidence (geometry) , sexually transmitted disease , gynecology , dermatology , antibiotics , immunology , microbiology and biotechnology , physics , optics , biology , syphilis , human immunodeficiency virus (hiv)
Trichomoniasis is frequent, parasitic and sexually transmitted infection of genitourinary tract. It is treated by metronidazole (5-nitroimidazole), according to protocol recommended by Center for Disease Control (CDC, formerly called: Communicable Disease Center) [19]. The resistance of Trichomonas vaginalis (TV) strains to metronidazole (MND) was described in USA in 1960, and later on in many European countries [8, 9, 10, 11, 12, 13]. In these cases, due to persistent trichomonas infection, it is necessary to repeat MND treatment with moderate modification of dose and/or length of its application. Nevertheless, oncogenic and toxic effects of MND have to be taken into consideration.